Cargando…

CDCA4 as a novel molecular biomarker of poor prognosis in patients with lung adenocarcinoma

BACKGROUND: Because of the high incidence and poor prognoses of lung adenocarcinoma (LUAD), it is essential to identify cost-effective treatment options and accurate and reliable prognostic biomarkers. CDCA4 upregulation has been identified in many cancers. However, the prognostic importance of CDCA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Jianlong, Chen, Fengyu, Ouyang, Bin, Li, Xiuying, Zhang, Weidong, Gao, Xinglin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520321/ https://www.ncbi.nlm.nih.gov/pubmed/36185189 http://dx.doi.org/10.3389/fonc.2022.865756

Ejemplares similares

Overexpression of CDCA8 Predicts Poor Prognosis and Promotes Tumor Cell Growth in Prostate Cancer
por: Wan, Shun, et al.
Publicado: (2022)

CDCA2 promotes lung adenocarcinoma cell proliferation and predicts poor survival in lung adenocarcinoma patients
por: Shi, Run, et al.
Publicado: (2017)

The Higher Expression of CDCA2 Associated with Poor Prognosis in Glioma
por: Jin, Xin, et al.
Publicado: (2022)

CDCA3 is a prognostic biomarker for cutaneous melanoma and is connected with immune infiltration
por: Li, Tianhao, et al.
Publicado: (2023)

CDCA8 as an independent predictor for a poor prognosis in liver cancer
por: Shuai, Yu, et al.
Publicado: (2021)

Retracted: The Higher Expression of CDCA2 Associated with Poor Prognosis in Glioma
por: Markers, Disease
Publicado: (2023)

MDFI is a novel biomarker for poor prognosis in LUAD
por: Chen, Pengyu, et al.
Publicado: (2022)

Elevated Heterogeneous Nuclear Ribonucleoprotein C Expression Correlates With Poor Prognosis in Patients With Surgically Resected Lung Adenocarcinoma
por: Guo, Wei, et al.
Publicado: (2021)

Loss of IL-34 Expression Indicates Poor Prognosis in Patients With Lung Adenocarcinoma
por: Wang, Zhendong, et al.
Publicado: (2021)

NUF2 Expression Promotes Lung Adenocarcinoma Progression and Is Associated With Poor Prognosis
por: Jiang, Feng, et al.
Publicado: (2022)

CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC)
por: Tian, Yunhong, et al.
Publicado: (2018)

Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma
por: Yu, Zhenjun, et al.
Publicado: (2021)

Overexpression of CDCA8 promotes the malignant progression of cutaneous melanoma and leads to poor prognosis
por: Ci, Chao, et al.
Publicado: (2019)

Identifying and Validating Potential Biomarkers of Early Stage Lung Adenocarcinoma Diagnosis and Prognosis
por: Chen, Yingji, et al.
Publicado: (2021)

GPR115 Contributes to Lung Adenocarcinoma Metastasis Associated With LAMC2 and Predicts a Poor Prognosis
por: Wang, Yingjing, et al.
Publicado: (2020)

CDCA1/2/3/5/7/8 as novel prognostic biomarkers and CDCA4/6 as potential targets for gastric cancer
por: Li, Zhaoxing, et al.
Publicado: (2021)

High expression of CDCA7 predicts tumor progression and poor prognosis in human colorectal cancer
por: Li, Siman, et al.
Publicado: (2020)

The Comprehensive Analysis Illustrates the Role of CDCA5 in Breast Cancer: An Effective Diagnosis and Prognosis Biomarker
por: Gao, Yang, et al.
Publicado: (2023)

Upregulated FADD is associated with poor prognosis, immune exhaustion, tumor malignancy, and immunotherapy resistance in patients with lung adenocarcinoma
por: He, Miao, et al.
Publicado: (2023)

CDCA3 Predicts Poor Prognosis and Affects CD8(+) T Cell Infiltration in Renal Cell Carcinoma
por: Bai, Yuanyuan, et al.
Publicado: (2022)

Upregulation of Long Non-Coding RNA GCC2-AS1 Facilitates Malignant Phenotypes and Correlated With Unfavorable Prognosis for Lung Adenocarcinoma
por: Yu, Fengqiang, et al.
Publicado: (2021)

Molecular and Clinical Characterization of UBE2S in Glioma as a Biomarker for Poor Prognosis and Resistance to Chemo-Radiotherapy
por: Hu, Li, et al.
Publicado: (2021)

Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
por: Peng, Wenguang, et al.
Publicado: (2023)

A Greedy Algorithm-Based Stem Cell LncRNA Signature Identifies a Novel Subgroup of Lung Adenocarcinoma Patients With Poor Prognosis
por: Khadirnaikar, Seema, et al.
Publicado: (2020)

Over-Expression of Long Non-Coding RNA-AC099850.3 Correlates With Tumor Progression and Poor Prognosis in Lung Adenocarcinoma
por: Chen, Xi, et al.
Publicado: (2022)

Increased CDCA2 Level Was Related to Poor Prognosis in Hepatocellular Carcinoma and Associated With Up-Regulation of Immune Checkpoints
por: Tang, Mengying, et al.
Publicado: (2022)

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis
por: Zhao, Yue, et al.
Publicado: (2016)

Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma
por: Huang, Xinyang, et al.
Publicado: (2022)

Transketolase Serves as a Biomarker for Poor Prognosis in Human Lung Adenocarcinoma
por: Niu, Cong, et al.
Publicado: (2022)

Integrated Analysis of Cell Cycle–Related and Immunity-Related Biomarker Signatures to Improve the Prognosis Prediction of Lung Adenocarcinoma
por: Chen, Fangyu, et al.
Publicado: (2021)

Increased ASF1B Expression Correlates With Poor Prognosis in Patients With Gliomas
por: Zhu, Huaxin, et al.
Publicado: (2022)

Distinct expression of CDCA3, CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient
por: Phan, Nam Nhut, et al.
Publicado: (2018)

CDCA7 Facilitates Tumor Progression by Directly Regulating CCNA2 Expression in Esophageal Squamous Cell Carcinoma
por: Li, Hongyi, et al.
Publicado: (2021)

Screening microRNAs as potential prognostic biomarkers for lung adenocarcinoma
por: Dai, Hongshuang, et al.
Publicado: (2023)

SLC6A8 is a Potential Biomarker for Poor Prognosis in Lung Adenocarcinoma
por: Fan, Yongfei, et al.
Publicado: (2022)

Downregulated ARID1A by miR-185 Is Associated With Poor Prognosis and Adverse Outcomes in Colon Adenocarcinoma
por: Baldi, Salem, et al.
Publicado: (2021)

Loss of HES-1 Expression Predicts a Poor Prognosis for Small Intestinal Adenocarcinoma Patients
por: Kim, Jeong Won, et al.
Publicado: (2020)

Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Downregulated Expression of CLEC9A as Novel Biomarkers for Lung Adenocarcinoma
por: Miao, Fang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jg7rg71p9tihiiumb58caprdls